Upper respiratory tract infections have minimal impact on neffy’s pharmacokinetics or pharmacodynamics

This study demonstrates that upper respiratory tract infections do not appear to affect epinephrine exposure or maximum absorption after administration of neffy 2.0 mg.neffy appears to be a safe and effective epinephrine delivery option during upper respiratory tract infections.Epinephrine is the first-line treatment for severe allergic reactions, and epinephrine autoinjectors are the most common method of administration.However, despite injectable epinephrine's history of safety and efficacy, patients and caregivers are reluctant to administer injections.Most report delaying or failing to administer epinephrine during an allergic reaction, 1 resulting in an increased risk of complications and hospitalizations. 2 neffy (ARS Pharmaceuticals, San Diego, Calif) is an intranasal epinephrine delivery device developed as a needle-free option for emergency treatment of (type I) allergic reactions, including anaphylaxis.neffy's pharmacokinetic (PK) and pharmacodynamic (PD) profiles are bracketed by approved injection products in healthy volunteers. 3ecause of the high prevalence of upper respiratory tract infections (URTIs), it is important to characterize neffy's PKs and PDs among patients with URTIs.As such, we conducted the current study to evaluate the relative bioavailability of neffy 2.0 mg under URTI compared with normal conditions.